semaglutide and levothyroxine Together: Safety Guide These highlights do not include

Chronic nausea

By analogy with semaglutide (where the STEP-4 withdrawal trial demonstrated substantial weight regain within 12 months of discontinuation), researchers should anticipate that weight regain is likely following cessation of any GLP-1 class compound, including retatrutide

doi: 10.1177/1098612X211036793

Understanding this gap between promise and performance helps separate medical facts from marketing fiction

Certain symptoms should prompt a call or urgent evaluation

Key highlights Semaglutide is a popular and effective GLP-1 receptor agonist used for diabetes management and weight loss in overweight or obese individuals